Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2022-11-18 Regulatory Filings
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings
2022-11-18 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is titled as a Preliminary Proxy Statement and includes detailed information about a Special Meeting of Stockholders, including proposals to be voted on, voting procedures, and other related information. The document is not an announcement of a report, nor is it a financial report or earnings release. It is clearly a Proxy Solicitation & Information Statement, as it is intended to provide shareholders with information to solicit their votes for the special meeting. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2022-11-14 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-14 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. It includes Item 2.02 Results of Operations and Financial Condition, referencing a press release with quarterly financial results for the period ended September 30, 2022, and Item 7.01 Regulation FD Disclosure with a corporate presentation. The document itself does not contain detailed financial statements or comprehensive analysis but rather announces and furnishes a press release and presentation. The length is 4511 characters, which is relatively short and consistent with an 8-K filing. According to the rules, an 8-K announcing quarterly results and furnishing a press release is best classified as an Earnings Release (ER), as it is the initial announcement of quarterly financial results with key highlights only, not a full interim report (IR).
2022-11-10 English
FORM 4 SUBMISSION
Director's Dealing
2022-10-04 English
FORM 4 SUBMISSION
Director's Dealing
2022-10-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.